Antiretroviral drug resistance testing in adults with HIV infection -: Implications for clinical management

被引:492
作者
Hirsch, MS
Conway, B
D'Aquila, RT
Johnson, VA
Brun-Vézinet, F
Clotet, B
Demeter, LM
Hammer, SM
Jacobsen, DM
Kuritzkes, DR
Loveday, C
Mellors, JW
Vella, S
Richman, DD
机构
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Infectious Dis Unit, Boston, MA 02114 USA
[3] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
[4] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[5] Vet Affairs Med Ctr, Birmingham, AL USA
[6] Hop Bichat Claude Bernard, F-75877 Paris 18, France
[7] Hosp Badalona Germans Trias & Pujol, Fdn Irsa Caixa, Barcelona, Spain
[8] Hosp Badalona Germans Trias & Pujol, HIV Unit, Barcelona, Spain
[9] Univ Rochester, Rochester, NY 14627 USA
[10] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[11] Royal Free Hosp, Sch Med, London, England
[12] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA
[13] Ist Super Sanita, I-00161 Rome, Italy
[14] Univ Calif San Diego, San Diego, CA 92103 USA
[15] Vet Affairs Med Ctr, San Diego, CA 92161 USA
[16] Int AIDS Soc USA, San Francisco, CA 94129 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 279卷 / 24期
关键词
D O I
10.1001/jama.279.24.1984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives.-To review current knowledge of the biology and clinical implications of human immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for measuring resistance, and assess their use in clinical practice. Participants.-The international AIDS Society-USA assembled a panel of 13 physicians with expertise in basic science, clinical research, and patient care relevant to HIV resistance to antiretroviral drugs. Evidence.-We reviewed available data from published reports and presented at national and international research conferences. Basic science research, clinical trial results, and expert opinions were used to form the basis of this report, Data on methods for and characteristics of specific genotypic and phenotypic assays were obtained from manufacturers and service providers. Consensus Process.-The panel met regularly between October 1997 and April 1998, Panel subgroups developed and discussed different sections of the report before discussing them with the entire panel. Conclusions and suggested approaches to the use of resistance testing were determined by group consensus. Conclusions.-Plasma HIV RNA level and CD4(+) cell count are the primary values that should be used to guide the initiation of antiretroviral therapy and subsequent changes in therapy. Possible causes of treatment failure other than development of drug resistance that should be considered are adherence, drug potency, and pharmacokinetic issues, Genotypic and phenotypic testing for HIV resistance to antiretroviral drugs may prove useful for individual patient management. Assays under development need validation, standardization, and a clearer definition of their clinical roles, Possible current roles of resistance testing for choosing an initial regimen or changing antiretroviral therapy, as well as possible implications of the presence or absence of phenotypic resistance and genotypic changes, are discussed.
引用
收藏
页码:1984 / 1991
页数:8
相关论文
共 90 条
  • [1] [Anonymous], 1998, MMWR Recomm Rep, V47, P1
  • [2] BLOOR S, 1997, ANTIVIRAL THER S5, V2
  • [3] EFFECTS OF DISCONTINUATION OF ZIDOVUDINE TREATMENT ON ZIDOVUDINE SENSITIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES
    BOUCHER, CAB
    VANLEEUWEN, R
    KELLAM, P
    SCHIPPER, P
    TIJNAGEL, J
    LANGE, JMA
    LARDER, BA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (07) : 1525 - 1530
  • [4] HIV-1: Gambling on the evolution of drug resistance?
    Brown, AJL
    Richman, DD
    [J]. NATURE MEDICINE, 1997, 3 (03) : 268 - 271
  • [5] Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
    Caliendo, AM
    Savara, A
    An, D
    DeVore, K
    Kaplan, JC
    DAquila, RT
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (04) : 2146 - 2153
  • [6] Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24): : 1962 - 1969
  • [7] CARPENTER CJ, IN PRESS JAMA
  • [8] USE OF EVOLUTIONARY LIMITATIONS OF HIV-1 MULTIDRUG RESISTANCE TO OPTIMIZE THERAPY
    CHOW, YK
    HIRSCH, MS
    MERRILL, DP
    BECHTEL, LJ
    ERON, JJ
    KAPLAN, JC
    DAQUILA, RT
    [J]. NATURE, 1993, 361 (6413) : 650 - 654
  • [9] HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY
    COFFIN, JM
    [J]. SCIENCE, 1995, 267 (5197) : 483 - 489
  • [10] CONDA JH, 1997, ANTIVIRAL THER S5, V2